Lung cancer patients with a genetic variant linked to autoimmune disease may respond better to immunotherapy

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

source https://medicalxpress.com/news/2022-04-lung-cancer-patients-genetic-variant.html